PYC

2.70%

19.0¢ pyc therapeutics limited

Thanks Hottod. I’m not sure much goes over your head, from your...

First 51 Last

Share
Profile

Follow
Timbo57

135 Posts.

42

22/11/18

11:10

Post #: 36599737
Share
Originally posted by hottod ↑

Timbo, I’ll offer my thoughts, but please be aware that much of the scientific stuff goes right over my head!

What are the leading possibilities for PYC’s ASO program, if not DMD?

I’d certainly consider Spinal muscular atrophy (SMA) for the following reasons:

PYC, in collaboration with Murdoch University, has already completed animal model experiments in SMA which demonstrated preliminary signs of efficacy, lack of toxicity and delivery of ASOs to a range of locations. (Refer PYC Update, Dec 2016)

Murdoch University has a collaborative research agreement with Murdoch to establish the Sarepta Translational Laboratory, led by Profs. Steve Wilton and Sue Fletcher. The intention of the collaboration is to explore the applicability of PMOs for disease targets beyond Duchenne. Two example targets mentioned in a 2015 press release were cystic fibrosis and SMA.

The most common form of SMA (SMN related SMA) is caused by a deficiency of a motor neuron protein called SMN, a protein expressed in cells which is necessary for the survival of motor neurons. That deficiency is caused by a genetic defect in the SMN1 gene.

There is only one approved drug that I know of which treats SMA - Biogen’s Spinraza (nusinersen), which was approved by the FDA in December 2016. However, AveXis, a company recently acquired by Novartis, filed for FDA approval of its gene therapy for SMA last month, for which approval is expected in H1, 2019.

Spinraza is an ASO drug which is injected into the spine once a month and is already considered a blockbuster drug, having passed the US$1bn annual sales threshold in the September quarter this year. Doubtlessly Sarepta would like a piece of that market.

Just my thoughts… perhaps they’ll go for something totally under the radar!

Expand

Thanks Hottod. I’m not sure much goes over your head, from your posting i had you pegged as a scientist in this space. Good stuff.
PYC Price at posting: 2.9¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

First 51 Last

Add PYC (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change 0.005(2.70%)		Mkt cap ! $886.5M

Open	High	Low	Value	Volume
18.5¢	19.0¢	17.5¢	$508.8K	2.763M

Buyers (Bids)

No.	Vol.	Price($)
2	118941	18.5¢

Sellers (Offers)

Price($)	Vol.	No.
19.0¢	183634	2

Last trade - 16.10pm 14/11/2024 (20 minute delay)

PYC (ASX) Chart

Day chart unavailable

Thanks Hottod. I’m not sure much goes over your head, from your...

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks Hottod. I’m not sure much goes over your head, from your...

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News